期刊
EXPERT REVIEW OF HEMATOLOGY
卷 12, 期 9, 页码 723-732出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474086.2019.1636644
关键词
Immune thrombocytopenia; TPO-RA; eltrombopag; romiplostim; avatrombopag; Syk inhibitor; fostamatinib; FcRn; monoclonal antibody; platelet desialization; atorvastatin
类别
资金
- National Natural Science Foundation of China [81670118, 81470286]
- CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-002]
- Tianjin Key Project for Basic Research [18JCZDJC35000]
Introduction: Immune thrombocytopenia (ITP) is an autoimmune disease. Even though there are many treatments available, some patients remain resistant to multiple treatments. Therefore, it is very important to develop new treatment options. Areas covered: Here, the authors summarize several current and emerging treatments developed for ITP in recent years. They include a summary of their mechanisms of action and clinical trial results. Expert opinion: At present, the first-line treatment of ITP is glucocorticoid and intravenous immunoglobulin (IVIg). Other traditional therapies include splenectomy, thrombopoietin (TPO), rituximab and other immunosuppressive agents. The several emerging treatments developed recently for ITP may change the treatment pattern in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据